{"name":"Elusys Therapeutics","slug":"elusys-therapeutics","ticker":"","exchange":"","domain":"","description":"Elusys Therapeutics is a biopharmaceutical company founded in Pine Brook, New Jersey in 1998. The company specializes in the development of antibodies for the treatment infectious diseases. The antibodies are developed from protein complexes called heteropolymers which can bind to specific pathogens on one side and red blood cells on the other side.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2016-01-01","label":"Anthim first approved","drug":"Anthim","drugSlug":"obiltoxaximab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Anthim","genericName":"OBILTOXAXIMAB","slug":"obiltoxaximab","indication":"Inhalational anthrax","status":"marketed"}]}],"pipeline":[{"name":"Anthim","genericName":"OBILTOXAXIMAB","slug":"obiltoxaximab","phase":"marketed","mechanism":"Anthim works by binding to the protective antigen of anthrax toxin, neutralizing its effects.","indications":["Inhalational anthrax"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQWUoxZzBKRFFjR3hfeDRfMDBwMUoyV1JrOXZSVEhXSEtpazdJSXQzcU92LVp6MGZTZXFjZUxNbnpkbTRPcTVrTU1aMXZES3FUbk4tb3c4OVEyT3I0MHRXUFQtX1dNQy02UXBPMDN0VzNTUlB1QW5fbjlxX3h3NXVJT3Y0WS1sSGdL?oc=5","date":"2024-05-04","type":"pipeline","source":"OpenSecrets","summary":"Pharmaceuticals/Health Products Lobbying Profile - OpenSecrets","headline":"Pharmaceuticals/Health Products Lobbying Profile","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE1FZ0tnQ1FJX2RqVHlYdmxENnM5eUdPU1Z0VVZVaFBMbm1NV2NicUp5cUxLQWh5NkRWV0habzZoTGtCVEszbUZKdFVQM2xibDdYTlZBcTg3LWVuSDJSelBwTE9Wa2ljZzF2LThv?oc=5","date":"2019-05-27","type":"pipeline","source":"Straits Research","summary":"Anthrax Treatment Market Size, Global Trends & Growth Report By 2033 - Straits Research","headline":"Anthrax Treatment Market Size, Global Trends & Growth Report By 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE5KR0RLMXZ6MVhhVE9BdVU2TDQ2Z21fNjNzQlZlUWpQZ09xeUMwdEdDSlhwMmlwS2NCYThtWE1TT2lJUHdBSi0wVzhZY3ktclBDZHMtOG1B?oc=5","date":"2018-01-02","type":"pipeline","source":"Nature","summary":"People - Nature","headline":"People","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE9MOUxCaHBpTGdNX3R6dU15czhHTVhyQU9Pb19HOGlvWWJTQnJ6WFNIdnlBVnN2R2FZV0x2dVlxSVVUUF9EdEpvYVR6ZVM4WGYwUTJwU2F3?oc=5","date":"2017-12-31","type":"pipeline","source":"Nature","summary":"People - Nature","headline":"People","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQd1pUcGhzaXMxeVVfM2JqVkVmS0NtYVBnVTlMd1psOFB1Vk9TaGpEelZROHhzdXp3RERKRmI1MW9rd0I4U0w4TkNCN1BtaDRndUZIeW1XZ0pYU1hnS1k3MkhNMFdLRFVUYkJGR0hpQTkwbnBRMUJFOWlzUTlwczE1azlFcVA?oc=5","date":"2017-11-08","type":"regulatory","source":"DCAT Value Chain Insights","summary":"Parenteral Drugs: Tracking New Drug Approvals - DCAT Value Chain Insights","headline":"Parenteral Drugs: Tracking New Drug Approvals","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNODluNE5DdkZnVUc3WjBpSjFISzVPdDBXcGc3MWY5S00xdVJyVkxwbDM0Z25fTmtsTW5Ud25KRFo4TlVubzRGeG9TeHhSRzduU0c3dGlhS1UzSm53eHNKQWxWT0wtdmd0NVdoUF9HSW15V1ZUZURSTVhnUmdLNHRpWWRuQm9PQ3drb2JGYWpfTFgyU1RNdXFvbmdvU0MzQQ?oc=5","date":"2016-04-05","type":"regulatory","source":"Lab Manager","summary":"Drug Engineered at UT Austin to Treat Anthrax Gains FDA Approval - Lab Manager","headline":"Drug Engineered at UT Austin to Treat Anthrax Gains FDA Approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPZ1N0Q1lDcER2blBSNU9IdEpxcWk4eDF1VWpJUmxSbVE2N2YwUkE4dF9fZkRpeFRvWjBiWTdmY1pKLTd5X3VKbG8zcG1hOElpMUU1dUdmdWwwMkF6NmNHRFF0cVZfQm1fNFd0TFI0NHZ2RHMyUHZoU2RrR1lwTzRoNlg5U0l0bFM5TWpRdG5ib014V05JbFZDSU5aaw?oc=5","date":"2016-04-04","type":"regulatory","source":"The University of Texas at Austin","summary":"Drug Engineered at UT Austin to Treat Anthrax Gains FDA Approval - The University of Texas at Austin","headline":"Drug Engineered at UT Austin to Treat Anthrax Gains FDA Approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPbEZORGlFTG9hNk1KU0RpOXZPSlpxclVzWEpTenM4U0ZDeEZMdGVIYUE3WmljWkFEdEFyR1VOMlRTN2VGaW9fR18ydVpBWWRfUEtmUWRYemd3MERUWFpjU0xtTHY3TExweVZkU0JlZkxnREtDR2c0MndZc1pZdjZlVE5wbw?oc=5","date":"2015-02-26","type":"deal","source":"Genetic Engineering and Biotechnology News","summary":"JSR Group and Partners Acquire KBI Biopharma - Genetic Engineering and Biotechnology News","headline":"JSR Group and Partners Acquire KBI Biopharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE1uN2R3LUxyenhPQjZqc0RvTmZEaVNwNmQ3dzB2UHBzVmx1NEs0RjRUcHhXcWxHZk9VcnN0NHF2MWlLRFFZY3BFTXVWa244VUNzZjZXakJubW9CU2stSHFWTVZMcTlhYTZJZ1hqUXplZG9EQQ?oc=5","date":"2014-11-28","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"30 Top VC Firms for Biotechs - Genetic Engineering and Biotechnology News","headline":"30 Top VC Firms for Biotechs","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}